Showing 1791-1800 of 5957 results for "".
- Mount Sinai Recruits Internationally Recognized Ophthalmologists to Expand Leadershiphttps://modernod.com/news/mount-sinai-recruits-internationally-recognized-ophthalmologists-to-expand-leadership/2479609/Mount Sinai Health System announced the appointment of two new faculty members to expand leadership in the Department of Ophthalmology. Louis R. Pasquale, MD, FARVO, has been named Site Chair of Ophthalmology at The Mount Sinai Hospital and Mount Sinai Queens and will also serve as Vice Chair of
- Oertli Opens New Lean Factory Building in Berneck, Eastern Switzerlandhttps://modernod.com/news/oertli-opens-new-lean-factory-building-in-berneck-eastern-switzerland/2481922/Oertli Instrumente recently celebrated the opening of its new Lean Factory building at its main site in Berneck, Eastern Switzerland. The new Lean Factory covers 11,000 m2 and has the goal of increasing production efficiency and volumes in order to achieve the set growth targets. With a
- Nacuity Pharmaceuticals Advances Phase 1/2 Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progressionhttps://modernod.com/news/nacuity-pharmaceuticals-advances-phase-12-trial-evaluating-npi-002-intravitreal-implant-for-the-delay-of-cataract-progression/2481719/Nacuity Pharmaceuticals announced that a clinical trial site has been added to its phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.
- FDA Approves New Paragon Contact Lens Manufacturing Facility in Phoenixhttps://modernod.com/news/fda-approves-new-paragon-contact-lens-manufacturing-facility-in-phoenix/2476817/The FDA has approved Paragon Vision Science’s newly-constructed contact lens manufacturing site in suburban Phoenix, paving the way for the company’s ongoing domestic and global expansion. The Gilbert, Ariziona facility will produce advanced ortho-k products such as Paragon CRT for use in
- LensGen Will Present Early Results Of International “Grail” Study At ASCRShttps://modernod.com/news/lensgen-will-present-early-results-of-international-grail-study-at-ascrs/2476515/LensGen will share results from its “Grail” study at the ASCRS annual meeting in San Diego, May 3-7. The results will include the latest available data on patients who have been treated at two international sites.
- Santen Announces FDA Acceptance of Premarket Approval Application for DE-128 (MicroShunt) for Reviewhttps://modernod.com/news/santen-announces-fda-acceptance-of-premarket-approval-application-for-de-128-microshunt-for-review/2477976/Santen Pharmaceutical announced that the FDA has accepted the premarket approval (PMA) application for DE-128 (MicroShunt) for review. DE-128 is an investigational surgical glaucoma implant designed to reduce IOP in patients with primary open-angle glaucoma whose IOP is not controlled when using
- Santen Announces Topline Data for DE-128 (MicroShunt) Demonstrating Reductions in IOP and Medication Use in Patients With Glaucomahttps://modernod.com/news/santen-announces-topline-data-for-de-128-microshunt-demonstrating-reductions-in-iop-and-medication-use-in-patients-with-glaucoma/2476840/Santen Pharmaceutical announced the results of INN-005, a prospective, randomized, controlled, single-masked, multicenter study to assess the safety and effectiveness of DE-128 (MicroShunt) standalone, without concomitant cataract extraction. The study compared DE-128 implanted intraoperatively w
- Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Diseasehttps://modernod.com/news/kiora-pharmaceuticals-receives-12-million-in-research-tax-credits-to-advance-the-treatment-of-ophthalmic-disease/2481713/Kiora Pharmaceuticals announced its wholly owned subsidiaries have received, in aggregate, $1.2 million related to research tax incentives from the Austrian and Australian governments for research expenditures performed in 2021 and 2022. The funds were received as part of government incentiv
- Luminopia One Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial for Amblyopiahttps://modernod.com/news/luminopia-one-demonstrates-safety-and-efficacy-in-phase-3-pivotal-trial/2480274/Luminopia announced the publication of positive phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One. Published in Ophthalmology, the study was conducted at 21 academic and community sites in the U.S., in which childre
- Bio-Tissue Highlights Publication of DREAM Studyhttps://modernod.com/news/bio-tissue-highlights-publication-of-dream-study/2480079/Bio-Tissue highlighted the publication of the Dry Eye Amniotic Membrane (DREAM) study in Clinical Ophthalmology.[1] This retrospective study was conducted at 10 clinical sites in the United States, led by Marguerite McDonald, MD, and Hosam Sheha, MD. It demonstrates that a single applica